Navigation Links
Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
Date:11/29/2007

in patients with a hypersensitivity to escitalopram oxalate. As with other SSRIs, caution is indicated in the coadministration of tricyclic antidepressants (TCAs) with LEXAPRO. As with other psychotropic drugs that interfere with serotonin reuptake, patients should be cautioned regarding the risk of bleeding associated with the concomitant use of LEXAPRO with NSAIDs, aspirin, or other drugs that affect coagulation. The most common adverse events reported with LEXAPRO vs placebo (approximately 5 percent or greater and approximately twice that of placebo) were nausea, insomnia, ejaculation disorder, somnolence, increased sweating, fatigue, decreased libido, and anorgasmia. Further information on LEXAPRO is provided in the FDA approved Package Insert.

About Forest Laboratories and Its Products

Forest Laboratories (http://www.frx.com) is a U.S.-based pharmaceutical company dedicated to identifying, developing and delivering products that make a positive difference in peoples' lives. Forest Laboratories' growing product line includes LEXAPRO(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl D- aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. In addition to our growing product line, Forest also co-promotes the Daiichi Sankyo, Inc. products Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, Benicar HCT(R)* (olmesartan medoxomil-hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, and AZOR(TM)* (amlodipine and olmesartan medoxomil) a calcium c
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... -- Heska Corporation (Nasdaq: HSKA ) announces the ... Third Quarter 2014 Earnings Conference Call on the WebWhen:Wednesday, ... a.m. (EDT)Where: , www.heska.com (click on the ... of this website)How:Live over the Internet -- Simply log ... you may use the following teleconference access numbers:  Domestic: ...
(Date:10/25/2014)... Oct. 24, 2014   Metanome, Inc. , a ... services and data analysis, was the genomic sequencing provider ... Phase I/II clinical trial of SER 109, an Ecobiotic® ... Clostridium difficile infections (CDI). Metanome has ... R&D and clinical programs. Such genomic characterization has enabled ...
(Date:10/25/2014)... 2014 Best Practices designed the Medical ... a forum for sharing insights about the key ... mechanism for creating and sharing solutions through three ... from the Medical Affairs Consortium survey. ... the first roundtable of the 2014-2015 Medical Affairs ...
Breaking Medicine Technology:Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast 2Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Strong Participation in Best Practices' Medical Affairs Consortium Survey 2
... , KINGWOOD, Texas , ... (Pink Sheets: IMAI.PK) www.imaiinc.com announced today that ... purchase a minority interest in Assured Pharmacy, Inc. (Pink ... that is focused on selling prescription medications in the ...
... , WEST PALM BEACH, Fla. ... 50+ who have hearing loss, the AARP Hearing Care program, provided by HearUSA ... part of a nationwide rollout. , While one in 10 Americans have hearing ... suffer from this life altering condition. According to the National Institutes of ...
Cached Medicine Technology:International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain 2International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain 3HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today 2HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today 3HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today 4HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today 5
(Date:10/25/2014)... The Wehrman Collaborative, LLC (WeCo) ... disabled users by disabled users, has granted use ... Educational Resources of Burnsville, Minnesota, for their ... the Minnesota Alliance for Patient Safety of Minneapolis, ... website. Both organizations have met WeCo’s Standards ...
(Date:10/25/2014)... Raleigh, NC (PRWEB) October 25, 2014 ... patient who continued to receive pemetrexed (Alimta), after his ... to read the full story , just posted on ... study from Uji Tokushukai Medical Center in Japan suggests ... for mesothelioma patients who cannot tolerate higher ...
(Date:10/25/2014)... FRIDAY, Oct. 24, 2014 (HealthDay News) -- Researchers ... say their findings are cause for concern. ... that are raised for human consumption contribute to ... health, according to background information from the study. ... germs sicken about 2 million people and kill ...
(Date:10/22/2014)... 2014 At a time when the ... and athletes at all levels, the UPMC Sports ... current discussion where two powerful messages are lost: Concussions ... result in full recoveries every day. , In striving ... fact and research, UPMC and the Concussion Program are ...
(Date:10/22/2014)... October 22, 2014 For Dr. Iris Hunter, ... money; it’s an extension of her life’s mission. Her extensive ... as the owner of FirstLight HomeCare, make it clear that ... to me that my work makes a difference in the ... entrepreneurial spirit, so after much research, I felt ready to ...
Breaking Medicine News(10 mins):Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2
... Medical,Inc. (Nasdaq: NXTM ), a leading manufacturer of ... a $50.0 million credit,and security agreement from a group ... Merrill Lynch Business Services Inc., for a term of,42 ... million term loan and a $20.0,million revolving credit facility. ...
... Research Hospital have discovered a new signaling molecule that ... body. The finding could lead to the development of ... such as Type 1 diabetes; and for inflammatory diseases, ... , The St. Jude team discovered that specialized immune ...
... Conn., Nov. 21 Therap Services will host ... 5-7, 2007 in,Southbury, Connecticut. The 2nd Direct Support ... Support Professionals who are daily,users of Therap as ... Therap,s users and its developers and support staff., ...
... survey found , WEDNESDAY, Nov. 21 (HealthDay News) -- Older ... stress, a new study shows. , A team of University ... 53 to 85 who worked at least 20 hours per ... male, 87 percent were white, about 8 percent were black, ...
... Nov. 21 Susan G. Komen for the ... breast cancer research and,community-based outreach programs, is accepting ... who lost a,parent to breast cancer., (Logo: ... Award helps students cover the costs of,tuition, books, ...
... Region activates when a friend,s voice calls, scientists say , ... they,ve spotted a brain region that selectively emphasizes certain sounds, ... person,s name. , Researchers from the University of Washington, Seattle, ... the experimental method they used to detect brain activity associated ...
Cached Medicine News:Health News:NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital 2Health News:NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital 3Health News:St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases 2Health News:St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases 3Health News:Therap Services to Host 2nd Conference for Direct Support Professionals 2Health News:Jobs Don't Stress Most Older Workers 2Health News:Susan G. Komen for the Cure Provides Scholarships for Students Who Lost a Parent to Breast Cancer 2
... 8F Percutaneous Vascular Surgical (PVS) System consists of ... Perclose Knot Pusher. The Prostar XL 8F PVS ... two pairs of sutured needles as well as ... precisely control the needles during deployment. the Perclose ...
... The new solid-state IRIS Medical IQ ... the treatment of retinal disorders and ... represents its latest technological innovation and ... Minimum Intensity Photocoagulation (MIP) procedures in ...
... The AIA-360 is a sophisticated Aumated Immunoassay Analyzer ... analyzer has a footprint of 16 X 16 ... Its compact design is ideal for physician ... testing, such as cardiac panels, as well as ...
... Solitaire represents the latest in green laser ... for use in both the operating room ... preference testing and the most experienced ophthalmic ... is the premium 532nm photocoagulator - unique ...
Medicine Products: